AngioDynamics (ANGO)
Market Price (2/26/2026): $11.49 | Market Cap: $477.3 MilSector: Health Care | Industry: Health Care Equipment
AngioDynamics (ANGO)
Market Price (2/26/2026): $11.49Market Cap: $477.3 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 48% | Weak multi-year price returns3Y Excs Rtn is -84% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.7% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, and Targeted Therapies. | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.8% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.0% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% | ||
| Key risksANGO key risks include [1] its ongoing challenges in achieving consistent profitability and positive free cash flow and [2] the need to successfully scale new product platforms, Show more. |
| Low stock price volatilityVol 12M is 48% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, and Targeted Therapies. |
| Weak multi-year price returns3Y Excs Rtn is -84% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.7% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.8% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.0% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% |
| Key risksANGO key risks include [1] its ongoing challenges in achieving consistent profitability and positive free cash flow and [2] the need to successfully scale new product platforms, Show more. |
Qualitative Assessment
AI Analysis | Feedback
AngioDynamics (ANGO) stock has lost about 5% since 10/31/2025 because of the following key factors:
1. CEO Transition Announcement
AngioDynamics announced the planned retirement of its President and CEO, James C. Clemmer, on February 3, 2026. This leadership change, even with an extended transition period until November 30, 2026, likely introduced uncertainty among investors regarding the company's future strategic direction and operational execution, typically leading to a negative impact on stock valuation.
2. Lingering Concerns over Tariff Headwinds
The company continued to face anticipated tariff headwinds, estimated at $4 million to $6 million for fiscal year 2026. These tariffs were expected to dampen profit margins and adjusted EBITDA, contributing to investor caution and concerns about sustained profitability.
Show more
1. CEO Transition Announcement
AngioDynamics announced the planned retirement of its President and CEO, James C. Clemmer, on February 3, 2026. This leadership change, even with an extended transition period until November 30, 2026, likely introduced uncertainty among investors regarding the company's future strategic direction and operational execution, typically leading to a negative impact on stock valuation.
2. Lingering Concerns over Tariff Headwinds
The company continued to face anticipated tariff headwinds, estimated at $4 million to $6 million for fiscal year 2026. These tariffs were expected to dampen profit margins and adjusted EBITDA, contributing to investor caution and concerns about sustained profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -4.7% change in ANGO stock from 10/31/2025 to 2/26/2026 was primarily driven by a -5.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.03 | 11.46 | -4.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 301 | 307 | 2.2% |
| P/S Multiple | 1.6 | 1.5 | -5.9% |
| Shares Outstanding (Mil) | 41 | 42 | -0.9% |
| Cumulative Contribution | -4.7% |
Market Drivers
10/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ANGO | -4.7% | |
| Market (SPY) | 1.1% | 31.1% |
| Sector (XLV) | 9.1% | 8.8% |
Fundamental Drivers
The 29.3% change in ANGO stock from 7/31/2025 to 2/26/2026 was primarily driven by a 24.8% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.86 | 11.46 | 29.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 292 | 307 | 5.1% |
| P/S Multiple | 1.2 | 1.5 | 24.8% |
| Shares Outstanding (Mil) | 41 | 42 | -1.3% |
| Cumulative Contribution | 29.3% |
Market Drivers
7/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ANGO | 29.3% | |
| Market (SPY) | 9.4% | 28.5% |
| Sector (XLV) | 21.2% | 15.5% |
Fundamental Drivers
The 0.4% change in ANGO stock from 1/31/2025 to 2/26/2026 was primarily driven by a 7.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.41 | 11.46 | 0.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 286 | 307 | 7.3% |
| P/S Multiple | 1.6 | 1.5 | -4.9% |
| Shares Outstanding (Mil) | 41 | 42 | -1.5% |
| Cumulative Contribution | 0.4% |
Market Drivers
1/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ANGO | 0.4% | |
| Market (SPY) | 15.5% | 40.0% |
| Sector (XLV) | 8.6% | 29.0% |
Fundamental Drivers
The -12.0% change in ANGO stock from 1/31/2023 to 2/26/2026 was primarily driven by a -6.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.02 | 11.46 | -12.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 328 | 307 | -6.3% |
| P/S Multiple | 1.6 | 1.5 | -1.2% |
| Shares Outstanding (Mil) | 39 | 42 | -4.9% |
| Cumulative Contribution | -12.0% |
Market Drivers
1/31/2023 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ANGO | -12.0% | |
| Market (SPY) | 75.9% | 26.4% |
| Sector (XLV) | 23.5% | 25.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ANGO Return | 80% | -50% | -43% | 17% | 40% | -11% | -25% |
| Peers Return | 13% | -9% | 11% | 10% | 4% | -6% | 22% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| ANGO Win Rate | 67% | 25% | 33% | 50% | 67% | 50% | |
| Peers Win Rate | 47% | 50% | 57% | 53% | 55% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| ANGO Max Drawdown | 0% | -56% | -55% | -33% | -9% | -23% | |
| Peers Max Drawdown | -10% | -32% | -14% | -15% | -13% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BSX, MDT, PEN, MMSI, TFX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/26/2026 (YTD)
How Low Can It Go
| Event | ANGO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -80.1% | -25.4% |
| % Gain to Breakeven | 401.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -51.1% | -33.9% |
| % Gain to Breakeven | 104.6% | 51.3% |
| Time to Breakeven | 160 days | 148 days |
| 2018 Correction | ||
| % Loss | -43.1% | -19.8% |
| % Gain to Breakeven | 75.8% | 24.7% |
| Time to Breakeven | 546 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -63.1% | -56.8% |
| % Gain to Breakeven | 171.1% | 131.3% |
| Time to Breakeven | 4,481 days | 1,480 days |
Compare to BSX, MDT, PEN, MMSI, TFX
In The Past
AngioDynamics's stock fell -80.1% during the 2022 Inflation Shock from a high on 11/5/2021. A -80.1% loss requires a 401.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AngioDynamics (ANGO)
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
AI Analysis | Feedback
1. The **Boston Scientific** of specialized, minimally invasive devices for peripheral vascular disease and tumor ablation.
2. A focused **Medtronic** for innovative medical technologies in vascular care and oncology.
AI Analysis | Feedback
- Thrombectomy Systems: Devices like AngioVac and Auryon used to remove blood clots from the body.
- Vascular Access Devices: A range of catheters, including PICCs, midlines, and ports, designed for long-term intravenous access.
- Tumor Ablation Systems: Technologies such as Solero Microwave Ablation and NanoKnife, utilized for the targeted destruction of tumors.
- Drainage Catheters: Medical devices designed for the percutaneous drainage of fluids from various body cavities.
AI Analysis | Feedback
AngioDynamics (ANGO) sells primarily to other companies within the healthcare sector, rather than directly to individuals.
The company markets and sells its medical devices to a diversified customer base, primarily consisting of:
- Hospitals: These are a core customer segment, utilizing AngioDynamics' products in various departments such as interventional radiology, oncology, and vascular surgery.
- Clinics and Alternate Site Facilities: This category includes specialized clinics, outpatient surgical centers, and other healthcare facilities where medical procedures using AngioDynamics' devices are performed.
- Distributors: Internationally, AngioDynamics also sells its products through a network of independent distributors who then supply them to local healthcare providers.
AngioDynamics does not disclose specific major customer companies by name in its public filings, such as its annual 10-K reports. This indicates that its revenue is not concentrated with any single customer or a small group of customers, but rather is diversified across a broad base of healthcare institutions and distributors. Therefore, no specific public company customer names or symbols can be listed as major customers.
AI Analysis | Feedback
null
AI Analysis | Feedback
James C. Clemmer, President and Chief Executive Officer
Mr. Clemmer has served as President and Chief Executive Officer of AngioDynamics Inc. since April 2016. Before joining AngioDynamics, he was the President of the $1.8 billion medical supplies segment at Covidien PLC, where he was responsible for strategic and day-to-day operations across 23 product categories globally. Earlier in his career, he served as Group President at Kendall Healthcare, managing the U.S. business across five divisions and developing the strategic plan for the Medical Supplies segment before its spin-off from Tyco. Mr. Clemmer began his career at Sage Products, Inc., which was acquired by Covidien in 1999. He currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging.
Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer
Mr. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having previously served as Interim Chief Financial Officer since October 2019. He joined AngioDynamics in June 2008 as Corporate Counsel and later served as Senior Vice President and General Counsel. Prior to AngioDynamics, Mr. Trowbridge was Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. He started his career in the Mergers and Acquisitions and Securities Group at Cadwalader, Wickersham & Taft LLP.
Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International
Ms. Piccinini joined AngioDynamics in June 2021. She has over 25 years of leadership experience in the Medical Device/Technology industry, with a strong background in respiratory care. Most recently, she was CEO and a board member for Respiratory Motion, Inc., and Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Her prior roles include serving as President of EMEA at both Covidien and Stryker.
Benjamin Davis, Senior Vice President, Business Development, Strategy and R&D
Mr. Davis serves as the Senior Vice President, Corporate Development and Strategy of AngioDynamics.
Chad T. Campbell, Senior Vice President and General Manager, Global Vascular Access
Mr. Campbell has served as Senior Vice President of Vascular Access of AngioDynamics Inc. since May 2016. He is also listed as SVP & GM, Global Vascular Access.
AI Analysis | Feedback
Here are the key business risks for AngioDynamics (ANGO):-
Intense Competition and Rapid Technological Change
AngioDynamics operates in a highly competitive medical technology market, facing significant threats from competitors with substantially greater resources and continuous technological advancements. The company's ability to develop new products, maintain its patent portfolio, and avoid infringing on third-party technologies is crucial for its market position. -
Regulatory and Reimbursement Challenges
As a medical device company, AngioDynamics is subject to extensive regulation. Future actions by the FDA and other domestic and international regulatory agencies, along with healthcare reforms and government regulations, pose considerable risks. Obtaining and maintaining regulatory clearances or approvals for its products, as well as securing adequate reimbursement, are critical for market access and commercial success. -
Operational and Financial Performance Risks
AngioDynamics faces ongoing operational and financial challenges, including concerns about consistent profitability, negative earnings per share, and negative free cash flow. The company's ability to successfully scale new product platforms, such as NanoKnife, for broad clinician adoption and sustained demand is vital. Furthermore, overall economic conditions, including inflation, labor shortages, supply chain disruptions, and tariffs, continue to impact its financial performance.
AI Analysis | Feedback
The success and rapid market penetration of companies like Inari Medical, particularly with their FlowTriever and ClotTriever systems for mechanical thrombectomy in venous thromboembolism (VTE), represent a clear emerging threat to AngioDynamics' AngioVac system. AngioVac is a critical product for AngioDynamics, used for the aspiration of intraluminal thrombi. Inari Medical's dedicated and highly effective solutions for large-volume clot removal in the venous system directly compete with and increasingly challenge AngioDynamics' presence in this important market segment, potentially limiting AngioVac's growth and market share.
AI Analysis | Feedback
AngioDynamics (NASDAQ: ANGO) operates in several key medical technology markets, offering devices for peripheral artery disease, thrombus management, and interventional oncology. The addressable markets for their main products and services are sized as follows:
- Peripheral Artery Disease (PAD) Devices (including Auryon Atherectomy System): The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. North America held the largest share of this global market, accounting for 43.5% in 2024. The global laser atherectomy devices market, a segment within PAD treatment that includes AngioDynamics' Auryon system, had North America as its leading region in 2022 due to the high prevalence of PAD, advanced healthcare infrastructure, and adoption of minimally invasive procedures. The overall atherectomy devices market size was valued at USD 1.03 billion in 2024 and is expected to reach USD 1.93 billion by 2032 globally, with North America holding a 47.5% share in 2024. The U.S. peripheral vascular devices and accessories market size was estimated at USD 3.6 billion in 2024.
- Thrombus Management Devices (including AngioVac and AlphaVac): The global thrombectomy devices market size was valued at USD 1.37 billion in 2024 and is forecasted to reach USD 2.60 billion by 2033, growing at a CAGR of 7.4% during the forecast period (2025-2033). Another report estimates the mechanical thrombectomy devices market, which includes AngioDynamics' AngioVac and AlphaVac, to be valued at USD 1.51 billion in 2024 and predicted to reach USD 2.99 billion by 2034, growing at a 7.2% CAGR from 2025-2034. North America dominated the market for mechanical thrombectomy devices in 2023. The venous thromboembolism (VTE) market was projected to grow from $950 million in 2020 to $1.7 billion by 2027 globally, with an 8.7% annual growth.
- Interventional Oncology Products (including NanoKnife System): The global interventional oncology market size was valued at USD 2.18 billion in 2024 and is projected to grow to USD 4.04 billion by 2032, exhibiting a CAGR of 8.1% from 2025 to 2032. Another report states the global interventional oncology market size was estimated at USD 2.7 billion in 2024 and is projected to reach USD 4.38 billion by 2030, growing at a CAGR of 8.55% from 2025 to 2030. North America held the largest share of the interventional oncology market, accounting for 42.2% in 2024 and 41.87% in 2024. The U.S. market within North America is anticipated to experience lucrative growth.
AI Analysis | Feedback
AngioDynamics (symbol: ANGO) is poised for future revenue growth over the next 2-3 years, driven by several key factors within its MedTech segment. The company has strategically focused on high-growth platforms, and management's forward guidance and analyst commentary highlight specific areas of anticipated expansion. Here are 3-5 expected drivers of AngioDynamics' future revenue growth:- Growth in Mechanical Thrombectomy (AlphaVac and AngioVac): AngioDynamics expects continued strong year-over-year growth from its mechanical thrombectomy businesses, specifically AlphaVac and AngioVac. AlphaVac sales have shown significant sequential growth, and the AlphaVac F18 System received FDA clearance for treating pulmonary embolism (PE), expanding its addressable market. The company is also investing in an expanded Mechanical Thrombectomy sales force to support this growth, and the RECOVER AV clinical trial for AlphaVac in Europe is underway.
- Expansion and Adoption of NanoKnife: The NanoKnife platform is anticipated to be a significant contributor to future revenue. Total NanoKnife revenue has shown strong increases, with particularly robust growth in probe sales. Key commercial and clinical catalysts include the NanoKnife prostate FDA indication (expected December 2024) with a new CPT code effective January 1, 2025, which is expected to accelerate the adoption of higher-margin products.
- Continued Performance of the Auryon Atherectomy System: Auryon has demonstrated consistent double-digit growth over multiple consecutive quarters and is expected to continue as a solid contributor to AngioDynamics' growth. The AMBITION BTK trial for Auryon is also expected to begin enrollment soon, which could further drive its market presence and revenue.
- Overall MedTech Segment Expansion and Market Demand for Minimally Invasive Therapies: AngioDynamics has strategically transformed by divesting non-core assets and focusing on its high-growth MedTech segment. This segment has consistently shown strong growth and is projected to continue its upward trajectory, with expected net sales growth of 14% to 16% in fiscal year 2026. Analysts concur that growth will be propelled by increasing global demand for minimally invasive therapies.
AI Analysis | Feedback
Share Repurchases
- AngioDynamics announced a share repurchase program for up to $15.0 million of its outstanding common shares subsequent to fiscal year 2024.
- As of February 28, 2025, $13.3 million remained available under the $15.0 million authorized share repurchase program.
- The company repurchased shares in fiscal years 2024 and 2025.
Share Issuance
- The number of shares outstanding for AngioDynamics increased by 1.49% in one year prior to November 2025.
- Proceeds from the exercise of stock options and employee stock purchase plans were $43,000 in the first quarter of fiscal year 2025 and $234,000 in the first quarter of fiscal year 2026.
Outbound Investments
- In February 2024, AngioDynamics sold its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash, which included an upfront payment, an earnout, and a milestone payment.
- The company divested its Dialysis and BioSentry businesses for $100 million in cash in June 2023.
- AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC on July 27, 2021.
Capital Expenditures
- Capital expenditures were -$9.82 million in the last 12 months prior to November 2025.
- Historical capital expenditures were $4.30 million in fiscal year 2024, $3.81 million in fiscal year 2023, and $2.52 million in fiscal year 2022.
- AngioDynamics projects capital expenditures of $5 million for fiscal year 2026 and $6 million annually for fiscal years 2027-2030, representing approximately 2% of revenue.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AngioDynamics Earnings Notes | 12/16/2025 | |
| AngioDynamics Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 | |
| Day 8 of Gains Streak for AngioDynamics Stock with 17% Return (vs. 16% YTD) [9/3/2025] | 09/04/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ANGO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 87.53 |
| Mkt Cap | 9.3 |
| Rev LTM | 2,334 |
| Op Inc LTM | 367 |
| FCF LTM | 234 |
| FCF 3Y Avg | 256 |
| CFO LTM | 329 |
| CFO 3Y Avg | 338 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.3% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 14.5% |
| QoQ Delta Rev Chg LTM | 3.4% |
| Op Mgn LTM | 15.3% |
| Op Mgn 3Y Avg | 14.6% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 16.7% |
| CFO/Rev 3Y Avg | 15.1% |
| FCF/Rev LTM | 12.6% |
| FCF/Rev 3Y Avg | 11.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 9.3 |
| P/S | 3.4 |
| P/EBIT | 22.5 |
| P/E | 32.4 |
| P/CFO | 17.4 |
| Total Yield | 1.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.5% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.2% |
| 3M Rtn | -6.9% |
| 6M Rtn | 0.8% |
| 12M Rtn | -5.9% |
| 3Y Rtn | 19.6% |
| 1M Excs Rtn | -3.2% |
| 3M Excs Rtn | -9.1% |
| 6M Excs Rtn | -6.5% |
| 12M Excs Rtn | -22.5% |
| 3Y Excs Rtn | -54.1% |
Price Behavior
Price Behavior
| Market Price | $11.46 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 06/01/2004 | |
| Distance from 52W High | -16.0% | |
| 50 Days | 200 Days | |
| DMA Price | $11.38 | $10.81 |
| DMA Trend | up | down |
| Distance from DMA | 0.7% | 6.0% |
| 3M | 1YR | |
| Volatility | 50.2% | 48.1% |
| Downside Capture | 131.98 | 112.02 |
| Upside Capture | 76.41 | 112.17 |
| Correlation (SPY) | 21.0% | 39.7% |
ANGO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.18 | 0.74 | 1.12 | 0.86 | 1.00 | 0.99 |
| Up Beta | -0.91 | -0.71 | 1.06 | 1.17 | 0.62 | 0.91 |
| Down Beta | -1.46 | -0.24 | 0.31 | 0.50 | 1.13 | 1.03 |
| Up Capture | -76% | 19% | 94% | 106% | 112% | 64% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 18 | 29 | 65 | 118 | 356 |
| Down Capture | 442% | 284% | 184% | 80% | 125% | 104% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 22 | 31 | 56 | 126 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | 18.8% | 48.1% | 0.51 | - |
| Sector ETF (XLV) | 7.2% | 17.3% | 0.24 | 29.5% |
| Equity (SPY) | 17.1% | 19.4% | 0.69 | 39.6% |
| Gold (GLD) | 79.3% | 25.7% | 2.25 | -1.1% |
| Commodities (DBC) | 10.9% | 16.8% | 0.45 | 11.1% |
| Real Estate (VNQ) | 6.6% | 16.6% | 0.21 | 30.8% |
| Bitcoin (BTCUSD) | -23.4% | 45.1% | -0.46 | 23.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | -10.3% | 53.3% | -0.01 | - |
| Sector ETF (XLV) | 8.2% | 14.5% | 0.38 | 30.5% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 32.0% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | 7.3% |
| Commodities (DBC) | 10.8% | 19.0% | 0.45 | 7.5% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 28.8% |
| Bitcoin (BTCUSD) | 4.0% | 57.0% | 0.29 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | 1.1% | 47.6% | 0.20 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.55 | 34.6% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 36.7% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 5.1% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 11.9% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | 32.5% |
| Bitcoin (BTCUSD) | 66.3% | 66.8% | 1.06 | 12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/6/2026 | -13.5% | -23.1% | |
| 10/2/2025 | 6.1% | 0.5% | 9.7% |
| 7/15/2025 | -10.2% | -6.6% | -8.2% |
| 4/2/2025 | 12.4% | -6.8% | -4.9% |
| 1/8/2025 | 37.7% | 29.5% | 17.4% |
| 10/3/2024 | -16.7% | -20.5% | -12.5% |
| 7/16/2024 | 26.6% | 20.2% | 27.0% |
| 4/4/2024 | 5.3% | 12.7% | 0.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 9 |
| # Negative | 11 | 13 | 13 |
| Median Positive | 11.7% | 13.6% | 17.2% |
| Median Negative | -11.8% | -16.7% | -12.5% |
| Max Positive | 37.7% | 29.5% | 27.0% |
| Max Negative | -27.0% | -34.8% | -37.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 11/30/2025 | 01/06/2026 | 10-Q |
| 08/31/2025 | 10/02/2025 | 10-Q |
| 05/31/2025 | 07/18/2025 | 10-K |
| 02/28/2025 | 04/02/2025 | 10-Q |
| 11/30/2024 | 01/08/2025 | 10-Q |
| 08/31/2024 | 10/03/2024 | 10-Q |
| 05/31/2024 | 07/25/2024 | 10-K |
| 02/29/2024 | 04/09/2024 | 10-Q |
| 11/30/2023 | 01/08/2024 | 10-Q |
| 08/31/2023 | 10/05/2023 | 10-Q |
| 05/31/2023 | 08/03/2023 | 10-K |
| 02/28/2023 | 03/31/2023 | 10-Q |
| 11/30/2022 | 01/06/2023 | 10-Q |
| 08/31/2022 | 10/11/2022 | 10-Q |
| 05/31/2022 | 07/22/2022 | 10-K |
| 02/28/2022 | 04/07/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weiss, Lawrence T | SVP, Chief Legal Officer | Direct | Buy | 10222025 | 11.81 | 10,000 | 118,100 | 1,105,381 | Form |
| 2 | Trowbridge, Stephen A | EVP and CFO | Direct | Buy | 10142025 | 11.16 | 890 | 9,932 | 2,863,980 | Form |
| 3 | Clemmer, James C | President and CEO | Direct | Buy | 10092025 | 11.15 | 10,000 | 111,500 | 9,840,198 | Form |
| 4 | Nighan, Warren Jr | SVP Quality and Regulatory | Direct | Sell | 1172025 | 12.31 | 4,060 | 49,979 | 514,767 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.